EUR-Lex Access to European Union law
This document is an excerpt from the EUR-Lex website
Document 52021M10486
Prior notification of a concentration (Case M.10486 — CDPQ/Centerbridge/Medical Solutions) Candidate case for simplified procedure (Text with EEA relevance) 2021/C 398/13
Prior notification of a concentration (Case M.10486 — CDPQ/Centerbridge/Medical Solutions) Candidate case for simplified procedure (Text with EEA relevance) 2021/C 398/13
Prior notification of a concentration (Case M.10486 — CDPQ/Centerbridge/Medical Solutions) Candidate case for simplified procedure (Text with EEA relevance) 2021/C 398/13
PUB/2021/770
OJ C 398, 1.10.2021, p. 19–20
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
1.10.2021 |
EN |
Official Journal of the European Union |
C 398/19 |
Prior notification of a concentration
(Case M.10486 — CDPQ/Centerbridge/Medical Solutions)
Candidate case for simplified procedure
(Text with EEA relevance)
(2021/C 398/13)
1.
On 22 September 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).This notification concerns the following undertakings:
|
— |
Caisse de dépôt et placement du Québec (‘CDPQ’, Canada), |
|
— |
Centerbridge Partners, L.P. (‘Centerbridge’, USA), |
|
— |
Medical Solutions LLC (‘Medical Solutions’, USA). |
CDPQ and Centerbridge acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of Medical Solutions.
The concentration is accomplished by way of purchase of shares.
2.
The business activities of the undertakings concerned are:|
— |
for CDPQ: globally active long-term institutional investor managing funds primarily for public and para-public pension and insurance plans, |
|
— |
for Centerbridge: global investment management firm active across investment disciplines from private equity to credit and related strategies, and real estate, |
|
— |
for Medical Solutions: staffing agency specialising in placing registered nurses, allied healthcare professionals, interim clinical leaders, and non-clinical professionals. |
3.
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.
4.
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
Case M.10486 — CDPQ/Centerbridge/Medical Solutions
Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:
Email: COMP-MERGER-REGISTRY@ec.europa.eu
Fax +32 22964301
Postal address:
|
European Commission |
|
Directorate-General for Competition |
|
Merger Registry |
|
1049 Bruxelles/Brussel |
|
BELGIQUE/BELGIË |
(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).